Viatris Inc, founded in 2020 and headquartered in Canonsburg, Pennsylvania, operates with the purpose of providing access to high-quality medicines, focusing on sustainability and patient-centric healthcare. The company offers a broad portfolio of generic and brand-name pharmaceuticals, encompassing a diverse range of therapeutic areas including infectious diseases, diabetes, and oncology.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| VTRS 1.65% 2025-06-22 USDViatris Inc | United States | 2025-06-22 | 1.650 | 4.70 |
| VTRS 2.30% 2027-06-22 USDViatris Inc | United States | 2027-06-22 | 2.300 | 4.56 |
| VTRS 2.70% 2030-06-22 USDViatris Inc | United States | 2030-06-22 | 2.700 | 4.92 |
| VTRS 2.70% 2030-06-22 USDViatris Inc | United States | 2030-06-22 | 2.700 | 4.92 |
| VTRS 2.70% 2030-06-22 USDViatris Inc | United States | 2030-06-22 | 2.700 | 4.92 |
| VTRS 3.85% 2040-06-22 USDViatris Inc | United States | 2040-06-22 | 3.850 | 6.29 |
| VTRS 4.00% 2050-06-22 USDViatris Inc | United States | 2050-06-22 | 4.000 | 6.65 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Viatris began issuing bonds shortly after its formation, with significant issuances including a $2.5 billion offering in early 2021, aimed at financing merger-related activities and refinancing existing debt. As of now, Viatris' bonds yield competitive rates compared to industry benchmarks, reflecting strong investor interest. The issuer's recent bond issuances include features such as callable options, providing flexibility in managing debt obligations. Moreover, the company has been actively engaging in buybacks and restructuring efforts, contributing to a stable outlook for its bondholders.